Acceleron Pharma

Investors & Media

Press Releases

Date Title and Summary
Toggle Summary Acceleron Presents Preliminary Interim Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) at the 2020 American Heart Association Scientific Sessions
– Treatment with sotatercept in first set of patients in the ongoing SPECTRA Phase 2 trial was associated with substantial improvements in hemodynamics, exercise tolerance and exercise capacity at week 24 – – Sotatercept was generally well tolerated, consistent with the previously reported safety
Toggle Summary Acceleron Presents New Data from the PULSAR Phase 2 Trial, Preclinical Research on Sotatercept in Pulmonary Arterial Hypertension (PAH) at the 2020 American Heart Association (AHA) Scientific Sessions
– Treatment with sotatercept in the ongoing PULSAR Phase 2 trial was associated with improvements in cardiac and pulmonary function at week 24 – – Presentation of echocardiography data from the PULSAR trial received AHA’s “Cardiopulmonary Best Abstract” Award – – Preclinical research shows
Toggle Summary Acceleron Announces Clinical Trial Updates, Preclinical Presentation on Sotatercept in Pulmonary Arterial Hypertension at the 2020 American Heart Association (AHA) Scientific Sessions
– Presentation of cardiac and pulmonary function data from the ongoing PULSAR Phase 2 trial receives AHA’s “Cardiopulmonary Best Abstract” Award – – AHA sessions to include data from the ongoing SPECTRA Phase 2 trial – – Acceleron to host investor and analyst conference call and webcast with guest
Toggle Summary Acceleron Reports Third Quarter 2020 Operating and Financial Results
- Acceleron recognized approximately $19.3 million in royalty revenue for Q3 2020 from approximately $96 million in net sales of REBLOZYL ® (luspatercept-aamt) - - REBLOZYL, the first and only erythroid maturation agent, was approved by Health Canada for the treatment of transfusion-dependent
Toggle Summary Acceleron Announces Third Quarter 2020 REBLOZYL® Net Sales
- Acceleron expects to report approximately $19.3 million in royalty revenue for Q3 2020 from approximately $96 million in net sales of REBLOZYL ® (luspatercept-aamt) as reported by Bristol Myers Squibb - - Acceleron will report its full third quarter 2020 financial and operating results after the
Toggle Summary Acceleron Announces REBLOZYL® (luspatercept-aamt) Virtual Presentations at the 62nd American Society of Hematology Annual Meeting
– Data analyses from the Phase 3 MEDALIST and BELIEVE trials find treatment with luspatercept maintains health-related quality of life in patients with lower-risk myelodysplastic syndromes and transfusion-dependent beta-thalassemia, respectively – – Longitudinal analyses from the BELIEVE trial show
Toggle Summary Acceleron to Webcast Third Quarter 2020 Operating and Financial Results on November 5, 2020
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 26, 2020-- Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, November 5, 2020 at 5:00 p.m. EST to discuss its third quarter 2020 operating and financial results.
Toggle Summary Health Canada Approves REBLOZYL® (luspatercept), New Class of Treatment for Adult Patients Living with Beta Thalassemia
REBLOZYL ® is the first and only erythroid maturation agent approved for use in Canada MONTREAL & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 29, 2020-- Bristol Myers Squibb Canada (BMS) and Acceleron Pharma Inc. (NASDAQ:XLRN) announced today that Health Canada has approved REBLOZYL ® (luspatercept)
Toggle Summary Acceleron to Host Webcast Outlining the Design of Its Registrational Phase 3 STELLAR Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) on October 2, 2020
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 17, 2020-- Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced it will host a conference call
Toggle Summary Acceleron Appoints Laura J. Hamill to its Board of Directors
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 16, 2020-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today the appointment of Laura J.